Suppr超能文献

佛蒙特州阿片类药物使用障碍的中心辐射式护理模式:发展、实施与影响

Vermont Hub-and-Spoke Model of Care for Opioid Use Disorder: Development, Implementation, and Impact.

作者信息

Brooklyn John R, Sigmon Stacey C

机构信息

Department of Psychiatry (JRB, SCS); Department of Psychology (SCS), University of Vermont, Burlington, VT.

出版信息

J Addict Med. 2017 Jul/Aug;11(4):286-292. doi: 10.1097/ADM.0000000000000310.

Abstract

BACKGROUND

Opioid use disorders (OUDs) are reaching epidemic proportions in the United States, and many geographic areas struggle with a persistent shortage in availability of opioid agonist treatment. Over the past 5 years, Vermont addiction medicine physicians and public health leaders have responded to these challenges by developing an integrated hub-and-spoke opioid treatment network.

METHODS

In the present report, we review the development, implementation, and impact of this novel hub-and-spoke model for expanding OUD treatment in Vermont.

RESULTS

Vermont's hub-and-spoke system has been implemented state-wide and well-received by providers and patients alike. Adoption of this model has been associated with substantial increases in the state's OUD treatment capacity, with Vermont now having the highest capacity for treating OUD in the United States with 10.56 people in treatment per 1000. There has been a 64% increase in physicians waivered to prescribe buprenorphine, a 50% increase in patients served per waivered physician, and a robust bidirectional transfer of patients between hubs and spokes based upon clinical need. Challenges to system implementation and important future directions are discussed.

CONCLUSIONS

Development and implementation of a hub-and-spoke system of care has contributed substantially to improvements in opioid agonist treatment capacity in Vermont. This system may serve as a model for other states grappling with the current opioid use epidemic.

摘要

背景

阿片类药物使用障碍(OUDs)在美国正呈流行态势,许多地区都面临阿片类激动剂治疗可及性持续短缺的问题。在过去5年里,佛蒙特州的成瘾医学医生和公共卫生领导人通过建立一个综合性的中心辐射型阿片类药物治疗网络来应对这些挑战。

方法

在本报告中,我们回顾了这种新型中心辐射型模式在佛蒙特州扩大阿片类药物使用障碍治疗方面的发展、实施情况及影响。

结果

佛蒙特州的中心辐射型系统已在全州实施,并受到了医疗服务提供者和患者的一致好评。采用这种模式使该州的阿片类药物使用障碍治疗能力大幅提高,佛蒙特州目前是美国治疗阿片类药物使用障碍能力最高的州,每1000人中有10.56人接受治疗。获得丁丙诺啡处方豁免的医生增加了64%,每位获得豁免的医生服务的患者增加了50%,并且患者根据临床需求在中心和辐射点之间进行了强劲的双向转诊。讨论了系统实施面临的挑战和重要的未来发展方向。

结论

中心辐射型护理系统的开发和实施极大地促进了佛蒙特州阿片类激动剂治疗能力的提高。该系统可为其他正在应对当前阿片类药物使用流行问题的州提供一个模式。

相似文献

1
Vermont Hub-and-Spoke Model of Care for Opioid Use Disorder: Development, Implementation, and Impact.
J Addict Med. 2017 Jul/Aug;11(4):286-292. doi: 10.1097/ADM.0000000000000310.
2
The Washington State Hub and Spoke Model to increase access to medication treatment for opioid use disorders.
J Subst Abuse Treat. 2020 Jan;108:33-39. doi: 10.1016/j.jsat.2019.07.007. Epub 2019 Jul 19.
3
Preliminary results of the evaluation of the California Hub and Spoke Program.
J Subst Abuse Treat. 2020 Jan;108:26-32. doi: 10.1016/j.jsat.2019.07.014. Epub 2019 Aug 1.
4
Assessment of medication for opioid use disorder as delivered within the Vermont hub and spoke system.
J Subst Abuse Treat. 2019 Feb;97:84-90. doi: 10.1016/j.jsat.2018.11.003. Epub 2018 Nov 19.
6
Implementation of the hub and spoke model for opioid use disorders in California: Rationale, design and anticipated impact.
J Subst Abuse Treat. 2020 Jan;108:20-25. doi: 10.1016/j.jsat.2019.07.013. Epub 2019 Jul 27.
8
Vermont responds to its opioid crisis.
Prev Med. 2015 Nov;80:10-1. doi: 10.1016/j.ypmed.2015.04.002. Epub 2015 Apr 11.
10
West Virginia's model of buprenorphine expansion: Preliminary results.
J Subst Abuse Treat. 2020 Jan;108:40-47. doi: 10.1016/j.jsat.2019.05.005. Epub 2019 May 8.

引用本文的文献

1
Effectiveness of Washington State's hub and spoke model to improve opioid use disorder outcomes.
Health Aff Sch. 2025 Aug 7;3(8):qxaf157. doi: 10.1093/haschl/qxaf157. eCollection 2025 Aug.
2
The linkage between opioid treatment programs and recovery community centers: results of a survey of OTP directors.
Front Public Health. 2025 Aug 7;13:1532374. doi: 10.3389/fpubh.2025.1532374. eCollection 2025.
3
Aligning forces to accelerate healthcare transformation: Insights from the UPMC learning community.
Learn Health Syst. 2025 Feb 12;9(3):e10477. doi: 10.1002/lrh2.10477. eCollection 2025 Jul.
4
A learning health system model for addressing substance use: Denver Health Center for Addiction Medicine.
Learn Health Syst. 2025 Mar 27;9(3):e70003. doi: 10.1002/lrh2.70003. eCollection 2025 Jul.
5
Emergency Department-Based Medication for Opioid Use Disorder: A 5-Year Experience.
J Am Coll Emerg Physicians Open. 2025 Jun 3;6(4):100192. doi: 10.1016/j.acepjo.2025.100192. eCollection 2025 Aug.
6
Identifying opioid agonist treatment prescriber networks from health administrative data: A validation study.
PLoS One. 2025 May 16;20(5):e0322064. doi: 10.1371/journal.pone.0322064. eCollection 2025.
7
Beyond licensure: systemic reforms to expand evidence-based addiction treatment.
Health Aff Sch. 2025 Apr 18;3(5):qxaf086. doi: 10.1093/haschl/qxaf086. eCollection 2025 May.
8
Organizational perspectives on the impacts of scaling up overdose education and naloxone distribution in Kentucky.
Addict Sci Clin Pract. 2025 Mar 14;20(1):27. doi: 10.1186/s13722-025-00553-2.
9
Assessing inequities in buprenorphine treatment across the care cascade.
Drug Alcohol Depend. 2025 May 1;270:112636. doi: 10.1016/j.drugalcdep.2025.112636. Epub 2025 Feb 28.
10
Call to Action: Standardizing Follow-Up Care for Infants Prenatally Exposed to Opioids.
Hosp Pediatr. 2025 Mar 1;15(3):e121-e125. doi: 10.1542/hpeds.2024-008094.

本文引用的文献

1
Interim Buprenorphine vs. Waiting List for Opioid Dependence.
N Engl J Med. 2016 Dec 22;375(25):2504-2505. doi: 10.1056/NEJMc1610047.
5
National and State Treatment Need and Capacity for Opioid Agonist Medication-Assisted Treatment.
Am J Public Health. 2015 Aug;105(8):e55-63. doi: 10.2105/AJPH.2015.302664. Epub 2015 Jun 11.
6
Vermont responds to its opioid crisis.
Prev Med. 2015 Nov;80:10-1. doi: 10.1016/j.ypmed.2015.04.002. Epub 2015 Apr 11.
7
The untapped potential of office-based buprenorphine treatment.
JAMA Psychiatry. 2015 Apr;72(4):395-6. doi: 10.1001/jamapsychiatry.2014.2421.
8
Psychological predictors of retention in a low-threshold methadone maintenance treatment for opioid addicts: a 1-year follow-up study.
Subst Use Misuse. 2015 Jan;50(1):24-31. doi: 10.3109/10826084.2014.957769. Epub 2014 Sep 23.
9
Factors affecting noncompliance with buprenorphine maintenance treatment.
J Addict Med. 2014 Sep-Oct;8(5):345-50. doi: 10.1097/ADM.0000000000000057.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验